the oncology challenge · 4/9/2019 · newer therapy types emerging include immune-oncology, gene...

The Oncology Challenge Embrace Innovation. Pursue Outcomes. Manage Costs. © 2020 NantHealth, Inc. The Growing Complexity of Treatment Decisions Inevitable Shift to Patient-Centric Care How Do You Align High Quality Oncology Care with Appropriate Reimbursement? 240 1,716 2,250 1,100+ new cancer therapies in development 3 drug targets currently in evaluation 4 Clinical trials evaluating PD-1/L1 Immune checkpoint inhibitors 5 Newer therapy types emerging include immune-oncology, gene therapy and personalized vaccines Clinical trials assessing PD-1/L1 checkpoint inhibitors combined with other therapies 6 Patients are educating themselves on specific therapies, but unable to know and consider all options Enable High Quality Oncology Care Integrate Medical Policies Streamline Operational Workflows To learn more, visit www.nanthealth.com Indicate Payer Preferences Ensure Appropriate Reimbursement Increase in direct to consumer marketing by Pharma Genetic testing readily available to consumers Surge of Informed Patient Advocates working on behalf of patients for best outcomes The High Cost of Cancer Care Cancer drug costs expected to double in two years 1 Expected cost of new targeted drugs 2 $ 150 K 2 X 1, 2. Global Oncology Trends 2018, IQVIA™ Institute for Human Data Science, www.iqvia.com/institute/reports/global-oncology-trends-2018 3. Medicines in Development for Cancer, America’s Biopharmaceutical Companies, phrma-docs.phrma.org/files/dmfile/2018_MID_Cancer.pdf 4, 5, 6. Tang J. et al. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nature Reviews Drug Discovery. 17, pages 854–855 (2018) practices across the U.S. already use Eviti Connect to submit preauthorization for cancer treatment. 6,700+

Upload: others

Post on 16-Aug-2020

2 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

The OncologyChallenge

Embrace Innovation. Pursue Outcomes. Manage Costs.

The Growing Complexity of Treatment Decisions

Inevitable Shift to Patient-Centric Care

How Do You Align High Quality Oncology Care with Appropriate Reimbursement?

240 1,7162,2501,100+new cancer therapies

in development3drug targets currently

in evaluation4Clinical trials evaluating

PD-1/L1 Immune checkpoint inhibitors5

Newer therapy types emerging include immune-oncology, gene therapy and personalized vaccines

Clinical trials assessing PD-1/L1 checkpoint

inhibitors combined with other therapies6

Patients are educating themselves on specific therapies, but unable to know and consider

all options

Enable High QualityOncology

Care

IntegrateMedical Policies

StreamlineOperational Workflows

To learn more, visit www.nanthealth.com

IndicatePayer Preferences

EnsureAppropriate

Reimbursement

Increase in direct to consumer marketing

by Pharma

Genetic testing readily available to consumers

Surge of Informed Patient Advocates working on behalf of patients for

best outcomes

The High Cost of Cancer Care

Cancer drug costsexpected to double

in two years1

Expected cost ofnew targeted drugs2

$150K2X

1, 2. Global Oncology Trends 2018, IQVIA™ Institute for Human Data Science, www.iqvia.com/institute/reports/global-oncology-trends-20183. Medicines in Development for Cancer, America’s Biopharmaceutical Companies, phrma-docs.phrma.org/files/dmfile/2018_MID_Cancer.pdf

4, 5, 6. Tang J. et al. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nature Reviews Drug Discovery. 17, pages 854–855 (2018)

practices across the U.S. already use Eviti Connect to submit preauthorization for cancer treatment.

6,700+

Pediatric Massage Therapy in Oncology Clinic: Lessons ...massagetherapyfoundation.org/wp-content/uploads/... · Pediatric Massage Therapy in Oncology Clinic: Lessons Learned while

SnapShot: Immune Checkpoint Inhibitors€¦ · SnapShot: Immune Checkpoint Inhibitors Gabriel Abril-Rodriguez1 and Antoni Ribas1,2 1Department of Medicine, Division of Hematology-Oncology,

Cancer Therapy: Spectrum of MLTISSTEM RAIOLOG Imaging …€¦ · Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings1 Immune checkpoint inhibitors are a new

HEMATOLOGY/ONCOLOGY - Adaptive Biotechnologies · 2019-12-14 · HEMATOLOGY/ONCOLOGY. BACKGROUND Immune checkpoint blockade therapy for treating solid tumors is rising in popularity

Pediatric Oncology: Vaccination After Therapy - BC Cancer€¦ · Pediatric Oncology: Vaccination After Therapy Family Practice Oncology CME Day . November 2017 . S. Rod Rassekh

Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 … · 2020-06-13 · RI. has served as . Board of Director to Surface Oncology ... Takara Bio, Trieza, Truvax, Serametrix,

Combination anti CTLA-4 plus anti PD-1 checkpoint distinct from … · Immune checkpoint blockade therapy has become a critical pillar of cancer therapy. Here, we characterize the

Exploring the Role of Immune Checkpoint Inhibitor Therapy

RECEPTIVE MUSIC THERAPY IN ONCOLOGY: GUIDED IMAGERY …

Radiation Therapy 1.2.3 hhholdorf “Radiotherapy and Radiation Oncology”